Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®

Seminars in Cancer Biology

Volumn 13, Issue 6, 2003, Pages 409-415

  Sondak, Vernon K ^a   Sosman, Jeffrey A ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant therapy; Cancer vaccines; HLA antigens; Immunotherapy; Melanoma

Indexed keywords

HLA A1 ANTIGEN; IMMUNOLOGICAL ADJUVANT; MELACINE; PHOSPHORYL LIPID A; CANCER VACCINE; HLA ANTIGEN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CARBOHYDRATE ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; ACTIVE IMMUNIZATION; IMMUNOLOGY; REVIEW; SKIN TUMOR; TREATMENT OUTCOME;

CANCER VACCINES; CLINICAL TRIALS; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ACTIVE; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0742321971     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.09.004     Document Type: Review

References (31)

1. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:1999;281-287.
2. Livingston P. The unfulfilled promise of melanoma vaccines. Clin. Cancer Res. 7:2001;1837-1838.
3. Barnes D.H.W., Loutit J.F. Treatment of murine leukemia with X-rays and homologous bone marrow. Br. J. Haematol. 3:1957;241.
4. Renkvist N., Castelli C., Robbins P.F., Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50:2001;3-15.
5. Van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B.et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
6. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Sakaguchi K., Appella E.et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U.S.A. 91:1994;3515-3519.
7. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J.J., De Plaen E.et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:1994;921-930.
8. Coulie P.G., Brichard V., Van Pel A., Wolfel T., Schneider J., Traversari C.et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:1994;35-42.
9. Van den Eynde B., Peeters O., De Backer O., Gaugler B., Lucas S., Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:1995;689-698.
10. Robbins P.F., el-Gamil M., Li Y.F., Topalïan S.L., Rivoltini L., Sakaguchi K.et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J. Immunol. 154:1995;5944-5950.
11. Mazzocchi A., Storkus W.J., Traversari C., Tarsini P., Maeurer M.J., Rivoltini L.et al. Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J. Immunol. 157:1996;3030-3038.
12. Jager E., Jager D., Karbach J., Chen Y.T., Ritter G., Nagata Y.et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 191:2000;625-630.
13. Sabel M.S., Sondak V.K. Melanoma vaccines: breakthrough or bust? Cancer Investig. 20:2002;1114-1116.
14. Mitchell M.S., Harel W., Kempf R.A., Hu E., Kan-Mitchell J., Boswell W.D.et al. Active specific immunotherapy for melanoma. J. Clin. Oncol. 8:1990;856-869.
15. Mitchell M.S., Kan-Mitchell J., Kempf R.A., Harel W., Shau H.Y., Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 48:1988;5883-5893.
16. Elliott G.T., Mcleod R.A., Perez J., Von Eschen K.B. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin. Surg. Oncol. 2:1993;41-53.
17. Mitchell M.S., von Eschen K.B. Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proc. Am. Soc. Clin. Oncol. 16:1997;494a.
18. Mitchell M.S., Jakowatz J., Harel W., Stevenson L., Boswell W.D., Groshen S. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J. Clin. Oncol. 12:1994;402-411.
19. Vaishampayan U., Abrams J., Darrah D., Jones V., Mitchell M.S. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and IFN alpha. Clin. Cancer Res. 8:2002;3696-3701.
20. Mitchell M.S. Immunotherapy as part of combinations for the treatment of cancer. Int. Immunopharmacol. 3:2003;1051-1059.
21. Mitchell M.S., Abrams J., Kashani-Sabet M., Thompson J. Interim analysis of a phase III stratified randomized trial of Melacine + low-dose Intron-A versus high-dose Intron-A for resected stage III melanoma. Proc. Am. Soc. Clin. Oncol. 22:2003;709a.
22. Sondak V.K., Liu P.-Y., Tuthill R.J., Kempf R.A., Unger J.M., Sosman J.A.et al. Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. I. Overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol. 20:2002;2058-2066.
23. Mitchell M.S., Harel W., Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J. Clin. Oncol. 10:1992;1158-1164.
24. Sosman J.A., Unger J.M., Liu P.-Y., Flaherty L.E., Park M.S., Kempf R.A.et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine. II. Impact of HLA class I antigen expression on outcome. J. Clin. Oncol. 20:2002;2067-2075.
25. Sosman J.A., Unger J.M., Liu P.-Y., Kempf R., Flaherty L.E., Thompson J.et al. HLA-A2 and/or HLA-C3 expression defines a subset of T3N0 melanoma patients with improved overall survival from melacine vaccine: an updated analysis of SWOG 9035. Proc. Am. Soc. Clin. Oncol. 21:2002;340a.
26. Marincola F.M., Venzon D., White D., Rubin J.T., Lotze M.T., Simonis T.B.et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res. 52:1992;6561-6566.
27. Marincola F.M., Shamamian P., Rivoltini L., Salgaller M., Cormier J., Restifo N.P.et al. HLA associations in the antitumor response against malignant melanoma. J. Immunother. 18:1995;242-252.
28. Hoon D.S., Okamoto T., Wang H.J., Elashoff R., Nizze A.J., Foshag L.J.et al. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J. Clin. Oncol. 16:1998;1430-1437.
29. Howell W.M., Turner S.J., Collins A., Bateman A.C., Theaker J.M. Influence of TNFα and LTα single nucleotide polymorphisms on susceptibility to and prognosis in cutaneous malignant melanoma in the British population. Eur. J. Immunogenet. 29:2002;17-23.
30. Kamarashev J., Ferrone S., Seifert B., Boni R., Nestle F.O., Burg G.et al. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int. J. Cancer (Pred. Oncol.). 95:2001;23-28.
31. Balch C.M., Buzaid A.C., Soong S.-J., Atkins M.B., Cascinelli N., Coit D.G.et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19:2001;3635-3648.